In vivo, use the following dual-pathology platforms: (i) CRC/breast/chondrosarcoma xenografts or syngeneic tumors combined with pressure-overload (TAC) or doxorubicin cardiotoxicity; (ii) HFpEF models with implanted tumors to mirror cardio-oncology; and (iii) FXa-high states to test coagulation–PAR-2 coupling. This evidence concerns the gene F2RL1 and chondrosarcoma.